Literature DB >> 25824228

In vitro activities of amphotericin B, terbinafine, and azole drugs against clinical and environmental isolates of Aspergillus terreus sensu stricto.

Mariana S Fernández1, Florencia D Rojas1, María E Cattana1, María de Los Ángeles Sosa1, Cristina A Iovannitti2, Cornelia Lass-Flörl3, Gustavo E Giusiano1.   

Abstract

The antifungal susceptibilities of 40 clinical and environmental isolates of A. terreus sensu stricto to amphotericin B, terbinafine, itraconazole, and voriconazole were determined in accordance with CLSI document M38-A2. All isolates had itraconazole and voriconazole MICs lower than epidemiologic cutoff values, and 5% of the isolates had amphotericin B MICs higher than epidemiologic cutoff values. Terbinafine showed the lowest MICs. No significant differences were found when MICs of clinical and environmental isolates were compared.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25824228      PMCID： PMC4432133          DOI： 10.1128/AAC.00045-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  33 in total

1.  In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing.

Authors:  Cornelia Lass-Flörl; Ana Alastruey-Izquierdo; Manuel Cuenca-Estrella; Susanne Perkhofer; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2008-12-08       Impact factor: 5.191

2.  Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.

Authors:  Richa Misra; Abida Malik; Sanjay Singhal
Journal:  Indian J Pathol Microbiol       Date:  2011 Jan-Mar       Impact factor: 0.740

3.  Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

Authors:  A Espinel-Ingroff; D J Diekema; A Fothergill; E Johnson; T Pelaez; M A Pfaller; M G Rinaldi; E Canton; J Turnidge
Journal:  J Clin Microbiol       Date:  2010-06-30       Impact factor: 5.948

4.  Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

Authors:  A Espinel-Ingroff; M Cuenca-Estrella; A Fothergill; J Fuller; M Ghannoum; E Johnson; T Pelaez; M A Pfaller; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

5.  In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.

Authors:  Michael A Pfaller; Frederick Duncanson; Shawn A Messer; Gary J Moet; Ronald N Jones; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

6.  Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance.

Authors:  Klaus Leth Mortensen; Rasmus Hare Jensen; Helle Krogh Johansen; Marianne Skov; Tacjana Pressler; Susan Julie Howard; Howard Leatherbarrow; Emilia Mellado; Maiken Cavling Arendrup
Journal:  J Clin Microbiol       Date:  2011-04-20       Impact factor: 5.948

7.  Aspergillus terreus complex: an emergent opportunistic agent of Onychomycosis.

Authors:  Mariana S Fernández; Florencia D Rojas; María E Cattana; María de Los Ángeles Sosa; Magdalena L Mangiaterra; Gustavo E Giusiano
Journal:  Mycoses       Date:  2013-03-01       Impact factor: 4.377

8.  New insight into amphotericin B resistance in Aspergillus terreus.

Authors:  Gerhard Blum; Caroline Hörtnagl; Emina Jukic; Thomas Erbeznik; Thomas Pümpel; Hermann Dietrich; Markus Nagl; Cornelia Speth; Günter Rambach; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

9.  Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.

Authors:  John W Baddley; Kieren A Marr; David R Andes; Thomas J Walsh; Carol A Kauffman; Dimitrios P Kontoyiannis; James I Ito; S Arunmozhi Balajee; Peter G Pappas; Stephen A Moser
Journal:  J Clin Microbiol       Date:  2009-08-19       Impact factor: 5.948

10.  Cutaneous infection caused by Aspergillus terreus.

Authors:  Burcin Ozer; Aydiner Kalaci; Nizami Duran; Yunus Dogramaci; Ahmet Nedim Yanat
Journal:  J Med Microbiol       Date:  2009-06-05       Impact factor: 2.472
View more
  2 in total

1.  Multilocus Phylogeny and Antifungal Susceptibility of Aspergillus Section Circumdati from Clinical Samples and Description of A. pseudosclerotiorum sp. nov.

Authors:  J P Z Siqueira; D A Sutton; J Gené; D García; N Wiederhold; S W Peterson; J Guarro
Journal:  J Clin Microbiol       Date:  2017-01-04       Impact factor: 5.948

2.  Terbinafine prevents colorectal cancer growth by inducing dNTP starvation and reducing immune suppression.

Authors:  Li-Peng Hu; Wuqing Huang; Xu Wang; Chunjie Xu; Wei-Ting Qin; Dongxue Li; Guangang Tian; Qing Li; Yaoqi Zhou; Suyuan Chen; Hui-Zhen Nie; Yujun Hao; Jian Song; Xue-Li Zhang; Jan Sundquist; Kristina Sundquist; Jun Li; Shu-Heng Jiang; Zhi-Gang Zhang; Jianguang Ji
Journal:  Mol Ther       Date:  2022-06-27       Impact factor: 12.910
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.